Novel xanthine oxidase inhibitor studies. Part 3.¹ Convenient and general syntheses of 3-substituted 7H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-5(6H)-ones as a new class of potential xanthine oxidase inhibitors

Tomohisa Nagamatsu,*" Takayuki Fujita" and Kazuki Endo^b

- *^a Faculty of Pharmaceutical Sciences, Okayama University, Tsushima, Okayama 700-8530, Japan*
- ^b Biology Laboratory, Research and Development Division, Yamasa Syoyu Co., Choshi, Chiba 288-0056, Japan

Received (in Cambridge, UK) 22nd September 1999, Accepted 22nd October 1999

Convenient and general syntheses of 3-substituted 7*H*-pyrazolo[4,3-*e*]-1,2,4-triazolo[4,3-*c*]pyrimidin-5(6*H*)-ones (12), a new class of potent xanthine oxidase inhibitors, involving the oxidative cyclisation of 6-substituted 4-alkylidenehydrazino- or 4-arylmethylidenehydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidines (3 and 11) with 70% nitric acid as the key step, are reported. The hydrazones 3 and 11 were obtained by a versatile synthetic route *via* the key intermediates, 6-chloro-4-hydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidine 2 or oxypurinol 4, starting from 2,4,6-trichloropyrimidine-5carbaldehyde 1. Their inhibitory activities against bovine milk xanthine oxidase *in vitro* are also described; *i.e.* the pyrazolotriazolopyrimidines 12 were several hundred times more potent than allopurinol.


Introduction

Allopurinol, a well known drug clinically used for treatment of gout and hyperuricemia resulting from uric acid,²⁻⁴ has been reported as a potential inhibitor of xanthine oxidase (XO), which catalyzes the conversion of hypoxanthine and xanthine to uric acid.⁵ Allopurinol is relatively non-toxic and does not appear to interfere with anabolic processes within the cell, as judged by its lack of inhibition of the growth of bacteria or tumors.⁶ However, some allopurinol toxicities⁷ and a lifethreatening toxicity syndrome have been reported after its use.⁸ Although XO inhibitory activities have recently been discovered in some newly synthesized compounds and previously known compounds,9-15 no clinically effective XO inhibitors for the treatment of hyperuricemia have been developed since allopurinol was introduced for clinical use in 1963.^{2,6} We have recently discovered that 6-alkylidenehydrazino- or 6-arylmethylidenehydrazino-7*H*-purines (I) and the angular type purine analogues, 9H-1,2,4-triazolo[3,4-i]purines (II), have exhibited more potent bovine milk XO inhibitory activities than that of allopurinol.^{1,16,17}

In our recent communication,¹⁸ we reported the facile and general syntheses of 3- and/or 5-substituted 7*H*-pyrazolo-[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidines (III) as a new class of potential xanthine oxidase inhibitors. Herein we report full details of the versatile and general syntheses of the 3-substituted 7*H*-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-5(6H)-ones (III), involving the oxidative cyclisation of 6-substituted 4-alkylidenehydrazino- or 4-arylmethylidenehydrazino-1*H*-pyrazolo[3,4-d]pyrimidines as the key step. Furthermore, we also report here their inhibitory activities against bovine milk xanthine oxidase in comparison with allopurinol *in vitro*.

Results and discussion


In the preceding paper,¹ we have clarified that 9H-1,2,4-triazolo[3,4-*i*]purines (II), especially the 5-oxo or 5-thioxo derivatives, showed more potent bovine milk XO inhibitory



activities than allopurinol. Therefore, in this paper we tried to prepare 3-substituted 7*H*-pyrazolo[4,3-*e*]-1,2,4-triazolo[4,3-*c*]-pyrimidin-5(6*H*)-ones (III), which are analogous to the triazolopurines (II), as another new class of potential XO inhibitors. Few methods for synthesis of the pyrazolotriazolopyrimidines (III) have been reported in the journal^{19,20} or patent²¹ literature and several derivatives have been synthesised. However, none of the 5-substituted derivatives has been prepared up to now.

In the first place we tried to synthesise the key intermediate, 4-hydrazino-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-one **6** derived

from barbituric acid. The requisite starting material, 2,4,6trichloropyrimidine-5-carbaldehyde **1**, was prepared according to a literature method.²² Treatment of **1** with anhydrous hydrazine (4 equiv.) in 2-methoxyethanol at 0 °C afforded 6-chloro-4-hydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidine **2** in 79% yield (Scheme 1). Subsequent reaction of compound **2** with



Scheme 1 Reagents and conditions: i, anh. NH_2NH_2 , 2-methoxyethanol, 0 °C, 0.5 h; ii, RCHO, DMF, r.t., 10 h; iii, conc. HCl reflux, 1 h; iv, 10% HCl, reflux, 3 h; v, P_2S_5 , pyridine, reflux, 2 h; vi, 50% ethanolic NH_2NH_2 , reflux, 10 min; vii, anh. NH_2NH_2 , 2-methoxyethanol, 100 °C, 5 h; viii, 80% aq. NH_2NH_2 , 80–90 °C, 4 h; ix, RCHO, DMF, r.t., 10 h; x, urea, 2-ethoxyethanol, reflux, 5 h; xi, urea, 2-ethoxyethanol, reflux, 10 h; xii, urea, 2-ethoxyethanol, 36 h.

appropriate aldehydes (1.2 equiv.) in dimethylfumamide (DMF) at room temperature gave the corresponding hydrazones **3a–g** in 60–93% yields as shown in Tables 1 and 2. Further, heating compound **2** in concentrated hydrochloric acid (50 parts) under reflux for 1 hour gave oxypurinol **4** (58% yield), which was confirmed by direct comparison with an authentic sample.²³ The oxypurinol **4** was also obtained in a similar yield by heating the hydrazone **3b** (R = Ph) in 10% hydrochloric acid (100 parts) for 3 hours. Thiation of oxypurinol **4** by phosphorous pentasulfide gave the 6-oxo-4-thioxo derivative **5** (76% yield) following a literature procedure²³ and the reaction of **5** with excess 50% ethanolic hydrazine under reflux yielded the desired intermediate, 4-hydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidin-6(7*H*)-one **6**, in 71% yield.

On the other hand, heating compound 1 with excess anhydrous hydrazine at 100 °C or heating compound 2 with

excess 80% hydrazine hydrate at 80-90 °C afforded the 4,6dihydrazino derivative 7 in good yields. Subsequent reaction of compound 7 with appropriate aldehydes (3.0 equiv.) in DMF at room temperature gave the corresponding hydrazones 8b-d,f in excellent yields as shown in Tables 1 and 2. Next, in an attempt to convert the 6-chloro-4-hydrazino compound 2 to the 6-oxo-4-hydrazino derivative 6, compound 2 was reacted with urea (4.0 equiv.) in 2-ethoxyethanol under reflux for 5 hours. However, owing to the stability of the chloro group towards hydroxy substitution by urea or alkali, the intended compound 6 was not obtained, but 4-carbamoylhydrazino-6-chloro-1Hpyrazolo[3,4-d]pyrimidine 9, which resulted from carbamoylation of the hydrazino group at the 4-position, was formed in 60% yield. Heating under reflux the product 9 with urea (3.0 equiv.) in 2-ethoxyethanol afforded the desired tricyclic compound, 3-amino-7H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-5(6H)-one 10, in 18% yield. This compound 10 (29% yield) was also obtained by prolonged heating of 2 with urea under the same reaction conditions as mentioned above.

All new compounds **2**, **3** and **6–10** exhibited satisfactory elemental combustion analyses except for **2** and **6** and FAB-MS, IR and ¹H NMR spectral data consistent with the structures. In particular, the structure of the product **10** was confirmed by the presence of a two-proton broad singlet signal at δ 7.94 and one-proton signals at δ 12.27 and 13.10 in the ¹H NMR spectrum attributable to the amino and imino groups and by the presence of peaks at 3370 (v_{as} NH), 3260 (v_{s} NH), 1720 (v C=O) and 1685 (δ NH) cm⁻¹ in the IR spectrum attributable to amino and carbonyl groups. It was clarified that the substitution reaction of the chloro group by hydroxy was difficult in the pyrazolo-pyrimidine ring **2**, while in the pyrazolotriazolopyrimidine ring **10** it was easy.

The 4-hydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidin-6(7*H*)-one 6 as noted above was a versatile intermediate for the preparation of the 7H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidine ring system. Thus the hydrazinopyrazolopyrimidine 6 could be converted to the hydrazones 11b, e-r (63-95% yields) by reaction with an appropriate aldehyde (1.5 equiv.) in DMF at room temperature (Scheme 2 and Tables 3 and 4). The hydrazones 11b, e-p, r were subsequently cyclised to the corresponding 3substituted 7*H*-pyrazolo[4,3-*e*]-1,2,4-triazolo[4,3-*c*]pyrimidin-5(6H)-ones 12b, e-p, r by heating with 70% nitric acid (1.2 equiv.) at 100 °C in 60–91% yields (Method A) (Tables 5 and 6). In the case of compound 11q possessing a 4-hydroxybenzylidenehydrazino group as the substituent at the 4-position, the 3-(4-hydroxy-3-nitrophenyl) derivative 12s was obtained by oxidative cyclisation-nitration in 52% yield. Oxidative cyclisation was also accomplished by heating compounds 11e, g, h, k, **m**-**o**, **q** with diethyl azodicarboxylate (DEAD) (3–7 equiv.) under reflux in 50-67% yields (Method B). Moreover, the 3-alkyl derivatives 12a-d were synthesised by treatment of compound 6 with an appropriate trialkyl orthoester (5.0 equiv.) in trifluoroacetic acid at room temperature (Method C) or heating compound 6 with trialkyl orthoesters (3.0 equiv.) in DMF at 100 °C (Method D) in 54-83% yields. In the light of this multiple step synthesis, a one-pot oxidative cyclisation starting from the 6-chloro-4-hydrazones 3a-g would be attractive. Indeed, heating the hydrazones 3a-g with 70% nitric acid (5.0) equiv.) in DMF at 100 °C afforded the desired 3-substituted 7H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-5(6H)-ones 12e, g, h, k, m, n, r accompanied by hydrolytic dechlorination in 60–85% yields (*Method E*).

All new compounds **11** and **12** exhibited satisfactory elemental combustion analyses and FAB MS, IR and ¹H NMR spectral data consistent with the structures as indicated in Tables 3–6.

Xanthine oxidase inhibitory results

The novel pyrazolopyrimidines 2, 3, 6, 8 and 11 and pyrazolo-

Table 1	Preparative,	physical and	l analytical	data for the	compounds 3a–g , 8	8b-d,f
---------	--------------	--------------	--------------	--------------	---------------------------	--------

	Yield (%) Mp/°C			Found (%			
Compound (Formula)			Recrystn. solvent " $(R_{\rm f}, {\rm solvent \ system \ }^b)$	С	Н	N	$m/z MH^+$
3a	60	250	AcOEt	52.9	6.5	28.5	295/297
C ₁₃ H ₁₉ ClN ₆			(0.78, A)	(53.0)	(6.5)	(28.5)	
3b	93	>300	DMF	52.4	3.7	30.6	273/275
C ₁₂ H ₉ ClN ₆			(0.56, A)	(52.85)	(3.3)	(30.8)	
3c	89	>300	EtOH–DMF	49.9	2.8	29.2	291/293
C ₁₂ H ₈ ClFN ₆			(0.60, A)	(49.6)	(2.8)	(28.9)	
3d	76	>300	EtOH–DMF	46.7	2.4	27.0	307/309/311
$C_{12}H_8Cl_2N_6$			(0.64, A)	(46.9)	(2.6)	(27.4)	
3e	78	>300	EtOH–DMF	54.0	4.1	29.1	287/289
C ₁₃ H ₁₁ ClN ₆			(0.61, A)	(54.5)	(3.9)	(29.3)	
3f	79	>300	EtOH–DMF	51.7	3.8	27.7	303/305
C ₁₃ H ₁₁ ClN ₆ O			(0.57, A)	(51.6)	(3.7)	(27.8)	
3g	70	>300	EtOH–DMF	45.6	2.7	30.6	318/320
C ₁₂ H ₈ ClN ₇ O ₂			(0.49, A)	(45.4)	(2.5)	(30.9)	
8b	87	298-300	EtOH–DMF	60.7	4.8	29.9	357
$C_{19}H_{16}N_8 \cdot H_2O$			(0.60, B)	(60.95)	(4.85)	(29.9)	
8c	93	>300	EtOH–DMF	54.1	4.1	26.4	393
$C_{19}H_{14}F_2N_8 \cdot 3/2 H_2O$			(0.61, B)	(54.4)	(4.1)	(26.7)	
8d	75	>300	EtOH–DMF	50.2	3.7	24.6	425/427/429
$C_{19}H_{14}Cl_2N_8 \cdot 3/2 H_2O$			(0.68, B)	(50.45)	(3.8)	(24.8)	
8f	77	276	EtOH–DMF	57.7	5.1	25.7	417
$C_{21}H_{20}N_8O_2 \cdot H_2O$			(0.62, B)	(58.1)	(5.1)	(25.8)	

 $C_{21}\Pi_{20}\Pi_8 O_2^{-1}\Pi_2 O_1^{-1}$

^{*a*} All compounds **3** and **8** were obtained as colourless or pale yellow powdery crystals except for **3g** (yellow). ^{*b*} Solvent systems: (A) AcOEt–*n*-hexane (4:3 v/v), (B) AcOEt–EtOH (9:1 v/v).

Table 2	1R and ¹ H NMR	spectroscopic data for	the compounds 3a–g , 8b–d , f
---------	---------------------------	------------------------	--


Compound	$v_{\rm max}$ (Nujol)/cm ⁻¹	$\delta_{\rm H}$ [60 MHz; (CD ₃) ₂ SO; Me ₄ Si]
3a	3180, 3100 (NH)	0.86 (3 H, J 6.8, CHCH ₂ [CH ₂] ₅ CH ₃), 1.31 (10 H, br s, CHCH ₂ [CH ₂] ₅ CH ₃), 2.15–2.60 (2 H, m, CHCH ₂ [CH ₂] ₅ CH ₃), 7.61 (1 H, t, J 6.6, CHCH ₂ [CH ₂] ₅ CH ₃), 8.18 (1 H, s, 3-H), 12.00 (1 H, br, 4-NH), 12.90 (1 H, br, 1-NH)
3b	3190, 3080 (NH)	7.40–7.60 (3 H, m, Ph- <i>m</i> , <i>p</i> H), 7.70–7.95 (2 H, m, Ph- <i>o</i> H), 8.28 (1 H, s, 3-H), 8.40 (1 H, s, C <i>H</i> -Ar), 12.44 (1 H, s, 4-NH), 13.75 (1 H, br s, 1-NH)
3c	3200, 3100 (NH)	7.32 (2 H, dd, J _{H,H} 8.8, J _{H,F} 9.1, Ar- <i>m</i> H), 7.90 (2 H, dd, J _{H,H} 8.8, J _{H,F} 5.9, Ar- <i>o</i> H), 8.27 (1 H, s, 3-H), 8.40 (1 H, s, C <i>H</i> -Ar), 12.45 (1 H, s, 4-NH), 13.70 (1 H, br, 1-NH)
3d ^{<i>a</i>}	3180, 3080 (NH)	7.55 (2 H, d, J 8.6, Ar- <i>m</i> H), 7.85 (2 H, d, J 8.6, Ar- <i>o</i> H), 8.26 (1 H, s, 3-H), 8.40 (1 H, s, C <i>H</i> -Ar), 12.54 (1 H, br, 4-NH), 13.70 (1 H, br, 1-NH)
3e	3190, 3080 (NH)	2.37 (3 H, s, CH ₃), 7.30 (2 H, d, <i>J</i> 7.9, Ar- <i>m</i> H), 7.70 (2 H, d, <i>J</i> 7.9, Ar- <i>o</i> H), 8.29 (1 H, s, 3-H), 8.38 (1 H, s, CH-Ar), 12.40 (1 H, br, 4-NH), 13.50 (1 H, br, 1-NH)
3f	3210, 3100 (NH)	3.84 (3 H, s, OCH ₃), 7.06 (2 H, d, <i>J</i> 8.8, Ar- <i>m</i> H), 7.78 (2 H, d, <i>J</i> 8.8, Ar- <i>o</i> H), 8.24 (1 H, s, 3-H), 8.39 (1 H, s, C <i>H</i> -Ar), 12.35 (1 H, br s, 4-NH), 13.60 (1 H, br, 1-NH)
$3g^{a}$	3190, 3090 (NH)	8.09 (2 H, d, J 8.8, Ar-oH), 8.32 (2 H, d, J 8.8, Ar-mH), 8.35 (1 H, s, 3-H), 8.46 (1 H, s, CH-Ar), 12.78 (1 H, br s, 4-NH), 13.90 (1 H, br, 1-NH)
8b	3240, 3180, 3140 (NH)	7.26–7.83 (10 H, m, Ph-H × 2), 8.19 (1 H, s, 6-CH-Ar), 8.24 (1 H, s, 3-H), 8.32 (1 H, s, 4-CH-Ar), 10.81 (1 H, br s, 6-NH), 11.78 (1 H, br, 4-NH), 13.07 (1 H, br, 1-NH)
8c	3250, 3170, 3130 (NH)	7.27 (2 H, dd, $J_{H,H}$ 8.8, $J_{H,F}$ 9.1, 6-Ar- <i>m</i> H), 7.32 (2 H, dd, $J_{H,H}$ 8.8, $J_{H,F}$ 9.1, 4-Ar- <i>m</i> H), 7.74 (2 H, dd, $J_{H,H}$ 8.8, $J_{H,F}$ 5.9, 6-Ar- <i>o</i> H), 7.87 (2 H, dd, $J_{H,H}$ 8.8, $J_{H,F}$ 5.8, 4-Ar- <i>o</i> H), 8.20 (1 H, s, 6-CH-Ar), 8.26 (1 H, s, 3-H), 8.33 (1 H, s, 4-CH-Ar), 10.93 (1 H, br s, 6-NH), 11.80 (1 H, br, 4-NH), 12.90 (1 H, br, 1-NH)
8d	3250, 3180, 3120 (NH)	7.45 (2 H, d, <i>J</i> 8.4, 6-Ar- <i>m</i> H), 7.51 (2 H, d, <i>J</i> 8.5, 4-Ar- <i>m</i> H), 7.74 (2 H, d, <i>J</i> 8.4, 6-Ar- <i>o</i> H), 7.80 (2 H, d, <i>J</i> 8.5, 4-Ar- <i>o</i> H), 8.17 (1 H, s, 6-C <i>H</i> -Ar), 8.28 (1 H, s, 3-H), 8.32 (1 H, s, 4-C <i>H</i> -Ar), 10.95 (1 H, br, 6-NH), 11.80 (1 H, br, 4-NH), 13.00 (1 H, br, 1-NH)
8f	3250, 3170, 3140 (NH)	3.75 (3 H, s, 6-OCH ₃), 3.81 (3 H, s, 4-OCH ₃), 6.95 (2 H, d, <i>J</i> 8.5, 6-Ar- <i>m</i> H), 7.06 (2 H, d, <i>J</i> 8.8, 4-Ar- <i>m</i> H), 7.60 (2 H, d, <i>J</i> 8.5, 6-Ar- <i>o</i> H), 7.77 (2 H, d, <i>J</i> 8.8, 4-Ar- <i>o</i> H), 8.12 (1 H, s, 6-CH-Ar), 8.20 (1 H, s, 3-H), 8.24 (1 H, s, 4-CH-Ar), 10.59 (1 H, br s, 6-NH), 11.66 (1 H, br, 4-NH), 12.83 (1 H, br, 1-NH)
" This compour	nd was measured at 200 MHz.	

triazolopyrimidines **12** prepared in this study were tested as inhibitors of bovine milk xanthine oxidase in a similar assay method ¹⁴ as previously reported. The inhibition (%) and IC_{50} (μ M) values of the compounds tested against bovine milk xanthine oxidase are shown in Table 7. Thus the introduction of both an aryl aldehyde hydrazone at the 4-position and an oxo group at the 6-position of the 1*H*-pyrazolo[3,4-*d*]pyrimidine ring led to markedly better activities in xanthine oxidase inhibition, these compounds being two orders of magnitude more active than allopurinol: IC_{50} values for **11g–k** and **11m–q** were *ca*. 0.08–0.4 μ M, whereas that for allopurinol was 24.3 μ M. Most

of the pyrazolotriazolopyrimidines **12a–s** showed potent inhibitory activities, being two or three orders of magnitude more active than allopurinol. Of these compounds, **12k** (R = $4\text{-ClC}_6\text{H}_4$) was the most active; it showed a 760-fold (IC₅₀ = 0.032 μ M) more potent bovine milk XO inhibitory activity than that of allopurinol.

Conclusion

Thus, this simple and general methodology provided a facile and convenient route to the preparation of 3-substituted 7*H*-



Scheme 2 Reagents and conditions: i, RCHO, DMF, r.t. or 40 °C, 10 h; ii, 70% HNO₃, DMF, 100 °C, 1–9 h; iii, DEAD, DMF, reflux, 5–9 h; iv, RC(OEt)₃, TFA, r.t., 1 h; v, RC(OEt)₃ or RC(OMe)₃, DMF, 100 °C, 1 h.

pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-5(6H)-ones (12), which were obtained by oxidative cyclisation of the corresponding 4-aldehyde hydrazones of 1H-pyrazolo[3,4-d]pyrimidines (3 and 11) with 70% nitric acid as the key step, as a new class of potential xanthine oxidase inhibitors. Their inhibitory activities against bovine milk xanthine oxidase in vitro were investigated, and some 4-arylmethylidenehydrazino-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones (11) exhibited from several times to several hundred times more potent activities than allopurinol. In addition, the tricyclic compounds, 3-aryl-7H-pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-5(6H)-ones (12) showed potent inhibitory activities, being ca. three orders of magnitude more active than allopurinol. They did not show any appreciable inhibition against the proliferation of T-cell acute lymphoblastic leukemia (CCRF-HSB-2) however.† Biological testing of the compounds in vivo is now ongoing and the results will be reported later.

Experimental

General

Mps were obtained on a Yanagimoto micro melting point

apparatus and were uncorrected. Microanalyses were measured by a Yanaco CHN Corder MT-5 apparatus. Mass spectra were recorded at 70 eV ionizing voltage with FAB ionization using a VG-70SE spectrometer and 3-nitrobenzyl alcohol or glycerol as a matrix. IR spectra were recorded using a JASCO FT/IR-200 spectrophotometer as Nujol mulls. ¹H NMR spectra were obtained using Hitachi FT-NMR R-1500 (60 MHz) and Varian VXR 200 MHz spectrometers. In all cases, chemical shifts are in ppm relative to $SiMe_4$ as internal standard and J values are given in Hz. All reagents were of commercial quality from freshly opened containers and were used without further purification. Organic solvents were dried by standard methods and distilled before use. Reaction progress was monitored by analytical thin layer chromatography (TLC) on pre-coated glass plates (silica gel 70 FM Plate-Wako) using the following solvent systems: (A) AcOEt-EtOH (4:1 v/v), (B) EtOH, (C) MeOH and others cited in the Tables. The products were visualized by UV light. Column chromatography was run on Daisogel IR-60 (63/210 µm, Daiso Co.). The reaction temperatures are indicated as the temperature of oil bath.

6-Chloro-4-hydrazino-1H-pyrazolo[3,4-d]pyrimidine 2

To a stirring solution of 2,4,6-trichloropyrimidine-5-carbaldehyde 1²² (3.0 g, 14.2 mmol) in 2-methoxyethanol (20 cm³) at 0 °C was added a solution of anhydrous hydrazine (1.82 g, 56.8 mmol) diluted with 2-methoxyethanol (18 cm³) in limited amounts for 30 min. After the reaction was complete, the precipitated crystals were collected by filtration and washed with water and EtOH to afford the pyrazolopyrimidine 2 (2.06 g, 79%) as pale yellow powdery crystals, mp > 300 °C; $R_{\rm f}$ (A) 0.64; v_{max}/cm^{-1} 3350 and 3260 (NH₂), 3160 and 3100 (NH) and $\delta_{\text{max}}/\text{cm}^{-1}$ 1660 (NH₂); δ_{H} [60 MHz; (CD₃)₂SO] 4.20 (2 H, br, NH₂), 8.50 (1 H, s, 3-H), 9.45 (1 H, br, 4-NH) and 13.40 (1 H, br, 1-NH); m/z (FAB, 3-nitrobenzyl alcohol matrix) 185 (MH⁺) and 187 (MH⁺ + 2). The product 2was obtained as a single compound and was used for the following reactions without further purification because it was difficult to purify since it was insoluble in usual solvents.

4-Alkylidenehydrazino- and 4-arylmethylidenehydrazino-6chloro-1*H*-pyrazolo[3,4-*d*]pyrimidines 3a–g; General procedure

A mixture of the hydrazinopyrazolopyrimidine 2 (1.0 g, 5.42 mmol) and an appropriate alkyl aldehyde or aryl aldehyde (6.50 mmol) in DMF (50 cm³) was stirred at room temperature for 10 hours. After the reaction was complete, the solution was evaporated under reduced pressure and the residue was triturated with EtOH or AcOEt to give crystals, which were collected by filtration and recrystallized from an appropriate solvent to afford the corresponding *hydrazones* 3a-g as shown in Tables 1 and 2.

1*H*-Pyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-dione 4 (oxypurinol)

(1) A mixture of the hydrazino derivative **2** (0.20 g, 1.08 mmol) with concentrated hydrochloric acid (10 cm³) was heated under reflux for 1 hour. After the reaction was complete, the solution was treated with activated charcoal and evaporated under reduced pressure; the residue was recrystallized from water to afford *oxypurinol* [95 mg, 58%; mp > 300 °C; R_f (A) 0.48; $v_{max}/$ cm⁻¹ 3180, 3150 and 3120 (NH) and 1720 (C=O)], which was identical with an authentic sample.²³

(2) The hydrazone **3b** (0.50 g, 1.83 mmol) in 10% aqueous HCl (50 cm³) was heated under reflux for 3 hours. After the reaction was complete, the solution was treated with activated charcoal and cooled to afford a deposit, which was collected by filtration. The filtrate was evaporated under reduced pressure and the residue was recrystallized from water to get the second

[†] We have found that some derivatives exhibited poor inhibitory activities against the proliferation of T-cell acute lymphoblastic leukemia (CCRF-HSB-2): the IC₅₀ for **11j**, 11 μM; for **11o**, 45 μM; for **12i**, 25 μM; for **12j**, 14 μM; for **12k**, 35 μM; for **12l**, 23 μM; for **12n**, 36 μM; for **12q**, 34 μM; for **12r**, 36 μM; for **12s**, 35 μM and for arabinosylcytosine, 0.061 μM.

Table 3	Preparative,	physical an	d analytica	l data for th	e compounds 11b, e–r
---------	--------------	-------------	-------------	---------------	----------------------

0	Destin	X7 11		December 1 and 4	Found (%	6) (Required)		
Compound (Formula)	Reaction temp/°C	Yield (%)	Mp/°C	Recrystn. solvent ^{<i>a</i>} ($R_{\rm f}$, solvent system ^{<i>b</i>})	C	Н	N	m/z MH	
11b	r.t.	89	>300	EtOH-DMF	43.4	4.2	43.65	193	
C ₇ H ₈ N ₆ O				(0.47, A)	(43.75)	(4.2)	(43.7)		
11e	r.t.	80	>300	EtOH–DMF	55.8	7.2	30.3	277	
C ₁₃ H ₂₀ N ₆ O·1/5 H ₂ O				(0.65, A)	(55.8)	(7.35)	(30.0)		
11f	r.t.	63	>300	EtOH–DMF	60.3	7.4	26.3	317	
$C_{16}H_{24}N_{6}O$				(0.47, B)	(60.7)	(7.65)	(26.6)		
11g	r.t.	85	>300	water-DMF	55.8	4.1	32.8	255	
$C_{12}H_{10}N_6O \cdot 1/5 H_2O$				(0.60, A)	(55.9)	(4.1)	(32.6)		
11ĥ	r.t.	74	>300	water-DMF	52.2	3.6	30.5	273	
C ₁₂ H ₉ FN ₆ O·1/4 H ₂ O				(0.64, A)	(52.1)	(3.5)	(30.4)		
11i	40	76	>300	EtOH-DMF	49.5	3.5	28.7	289/291	
C ₁₂ H ₉ ClN ₆ O				(0.64, A)	(49.9)	(3.1)	(29.1)		
11j	40	95	>300	EtOH-DMF	49.3	3.4	28.9	289/291	
$C_{12}H_9ClN_6O\cdot 1/5H_2O$				(0.65, A)	(49.3)	(3.2)	(28.75)		
11k	r.t.	95	>300	water-DMF	49.2	3.4	28.7	289/291	
C ₁₂ H ₉ ClN ₆ O·1/5 H ₂ O				(0.63, A)	(49.3)	(3.2)	(28.75)		
111	r.t.	83	>300	EtOH–DMF	43.3	3.1	24.9	333/335	
C ₁₂ H ₉ BrN ₆ O				(0.65, A)	(43.3)	(2.7)	(25.2)		
11m	r.t.	93	>300	DMF	57.4	4.5	31.1	269	
$C_{13}H_{12}N_6O \cdot 1/5 H_2O$				(0.67, A)	(57.4)	(4.6)	(30.9)		
11n	r.t.	87	>300	water-DMF	54.4	4.3	29.2	285	
C ₁₃ H ₁₂ N ₆ O ₂ ·1/5 H ₂ O				(0.62, A)	(54.2)	(4.3)	(29.2)		
110	40	85	>300	water-DMF	52.1	3.6	27.7	299	
$C_{13}H_{10}N_6O_3$				(0.67, A)	(52.35)	(3.4)	(28.2)		
11p	40	80	>300	water-DMF	52.6	3.4	28.2	299	
$C_{13}H_{10}N_6O_3$				(0.64, C)	(52.35)	(3.4)	(28.2)		
11q	40	85	>300	EtOH–DMF	53.2	4.0	30.7	271	
$C_{12}H_{10}N_6O_2$	-			(0.64, A)	(53.3)	(3.7)	(31.1)		
11r	r.t.	88	>300	EtOH–DMF	45.45	3.5	30.8	300	
$C_{12}H_9N_7O_3\cdot H_2O$		~ ~		(0.60, A)	(45.4)	(3.5)	(30.9)		

AcOEt-EtOH (9:1 v/v), (C) AcOEt-n-hexane-AcOH (8:4:1 v/v).

crop. The product was identical with oxypurinol (150 mg, 54%).

4-Hydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidin-6(7*H*)-one 6

To a mixture of hydrazine monohydrate (5.0 g, 99.9 mmol) and ethanol (5 cm³) was added 4,5-dihydro-4-thioxo-1*H*-pyrazolo-[3,4-*d*]pyrimidin-6(7*H*)-one **5**²³ (1.0 g, 5.95 mmol) and the mixture was heated under reflux for 10 min. After the reaction was complete, the precipitated crystals were collected by filtration and washed with water and EtOH to afford the *hydrazino derivative* **6** (0.70 g, 71%) as colourless powdery crystals, mp > 300 °C; R_f (B) 0.28; v_{max}/cm^{-1} 3360 and 3310 (NH₂), 3200, 3150 and 3100 (NH), 1710 (C=O) and δ_{max}/cm^{-1} 1670 (NH₂); δ_H [60 MHz; CF₃CO₂D] 8.72 (1 H, s, 3-H); *m/z* (FAB, 3-nitrobenzyl alcohol matrix) 167 (MH⁺). The product **6** was obtained as a single compound and was used for the following reactions without further purification because it was difficult to purify since it was insoluble in usual solvents.

4,6-Dihydrazino-1H-pyrazolo[3,4-d]pyrimidine 7

(1) To a stirring solution of 2,4,6-trichloropyrimidine-5-carbaldehyde 1^{22} (3.0 g, 14.2 mmol) in 2-methoxyethanol (20 cm³) at 0 °C was added anhydrous hydrazine (9.1 g, 283.9 mmol) dropwise. Then, the stirred mixture was heated at 100 °C for 5 hours. After the reaction was complete, the precipitated crystals were collected by filtration, washed with water and EtOH and recrystallized from water to afford the *dihydrazino derivative* 7 (1.94 g, 76%) as colourless powdery crystals, mp > 300 °C (Found: C, 33.1; H, 4.55; N, 61.5. C₅H₈N₈·1/5 H₂O requires C, 32.7; H, 4.6; N, 61.0%); $R_{\rm f}$ (C) 0.20; $v_{\rm max}/$ cm⁻¹ 3335, 3270 and 3230 (NH₂), 3180, 3120 and 3110 (NH) and $\delta_{\rm max}/{\rm cm^{-1}}$ 1650 and 1640 (NH₂); $\delta_{\rm H}$ [60 MHz; CF₃CO₂D] 8.81 (1H, s, 3-H); m/z (FAB, 3-nitrobenzyl alcohol matrix) 181 (MH⁺).

(2) To a stirring solution of 80% aqueous hydrazine hydrate (20 cm³, 320 mmol) was added 6-chloro-4-hydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidine **2** (2.0 g, 10.8 mmol) and the mixture was heated at 80–90 °C for 4 hours. After the same work-up as noted above, recrystallization of the crude crystals from water gave the *dihydrazino derivative* **7** (1.40 g, 72%).

4,6-Bis(arylmethylidenehydrazino)-1*H*-pyrazolo[3,4-*d*]pyrimidines 8b–d, f. General procedure

A mixture of the dihydrazino derivative 7 (0.60 g, 3.33 mmol) and an appropriate aldehyde (9.99 mmol) in DMF (20 cm³) was stirred at room temperature for 10 hours. After the reaction was complete, the solution was evaporated under reduced pressure and the residue was triturated with EtOH to give crystals, which were collected by filtration and recrystallized from a mixture of EtOH and DMF to afford the corresponding *bishydrazones* **8b–d**, **f** as shown in Tables 1 and 2.

4-Carbamoylhydrazino-6-chloro-1*H*-pyrazolo[3,4-*d*]pyrimidine 9

A mixture of the hydrazinopyrazolopyrimidine **2** (0.5 g, 2.71 mmol) and urea (0.65 g, 10.8 mmol) in 2-ethoxyethanol (25 cm³) was heated under reflux for 5 hours. After the reaction was complete, the solution was evaporated under reduced pressure to afford a solid. The solid was collected by filtration, washed with water and recrystallized from water to afford the *carbamoylhydrazino derivative* **9** (0.37 g, 60%) as colourless powdery crystals, mp > 300 °C (Found: C, 31.1; H, 2.9; N, 43.0. C₆H₆-ClN₇O·1/7 H₂O requires C, 31.3; H, 2.75; N, 42.6%); *R*_f (B)

Table 4	IR and ¹ H NMR spectroscopic data for the compounds 11h	, e−r
---------	--	-------

Compound	v _{max} (Nujol)/cm ⁻¹	$\delta_{\rm H}$ [200 MHz; (CD ₃) ₂ SO; Me ₄ Si]
11b	3175, 3130, 3070 (NH); 1700 (C=O)	2.01 (3 H, d, <i>J</i> 5.4, CHCH ₃), 7.69 (1 H, q, <i>J</i> 5.4, CHCH ₃), 8.35 (1 H, s, 3-H), 10.40 (1 H, br, 4-NH), 10.80 (1 H, br s, 7-NH), 12.85 (1 H, br, 1-NH)
11e	3175, 3135, 3070 (NH); 1710 (C=O)	0.86 (3 H, t, J 6.4, CHCH ₂ CH ₂ [CH ₂] ₄ CH ₃), 1.29 (8 H, br s, CHCH ₂ CH ₂ [CH ₂] ₄ CH ₃), 1.44–1.66 (2 H, m, CHCH ₂ CH ₂ [CH ₂] ₄ CH ₃), 2.24–2.42 (2 H, m, CHCH ₂ CH ₂ [CH ₂] ₄ CH ₃), 8.05 (1 H, t, J 5.4, CHCH ₂ CH ₂ [CH ₂] ₄ CH ₃), 8.28 (1 H, s, 3-H), 10.22 (1 H, br, 4-NH), 10.82 (1 H, br s, 7-NH), 12.95 (1 H, br, 1-NH)
11f	3175, 3135, 3070 (NH); 1700 (C=O)	1.28 (10 H, br s, CHCH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 1.44–1.64 (2 H, m, CHCH ₂ CH ₂ [CH ₂] ₅ -CH ₂ CH=CH ₂), 1.90–2.08 (2 H, m, CHCH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 2.22–2.42 (2 H, m, CHCH ₂ -CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 2.22–2.42 (2 H, m, CHCH ₂ -CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 4.86–5.06 (2 H, m, CHCH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 5.64–5.90 (1 H, m, CHCH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 5.64–5.90 (1 H, m, CHCH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 5.64–5.90 (1 H, m, CHCH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 8.28 (1H, s, 3-H), 10.28 (1 H, br, 4-NH), 10.82 (1 H, br s, 7-NH), 12.92 (1 H, br, 1-NH)
11g	3200, 3120, 3080 (NH); 1680 (C=O)	7.40–7.53 (3 H, m, Ph- <i>m</i> , <i>p</i> H), 7.80–7.90 (2 H, m, Ph- <i>o</i> H), 8.40 (1 H, s, 3-H), 8.46 (1 H, s, C <i>H</i> -Ar), 10.40 (1 H, br, 4-NH), 11.01 (1 H, br, 7-NH), 13.10 (1 H, br, 1-NH)
11h	3180, 3140, 3070 (NH); 1680 (C=O)	7.30 (2 H, dd, <i>J</i> _{H,H} 8.8, <i>J</i> _{H,F} 9.0, Ar- <i>m</i> H), 7.30 (2 H, dd, <i>J</i> _{H,H} 8.8, <i>J</i> _{H,F} 5.8, Ar- <i>o</i> H), 8.40 (1 H, s, 3-H), 8.45 (1H, s, <i>CH</i> -Ar), 10.40 (1 H, br, 4-NH), 11.00 (1 H, br, 7-NH), 13.09 (1 H, br, 1-NH)
11i ^a	3200, 3120, 3080 (NH); 1700 (C=O)	7.33–7.60 (3 H, m, 3'-H, 4'-H and 5'-H), 8.12–8.28 (1 H, m, 6'-H), 8.48 (1H, s, 3-H), 8.72 (1 H, s, CH-Ar), 10.35 (1 H, br s, 4-NH), 11.10 (1 H, br, 7-NH), 13.40 (1 H, br, 1-NH)
11j	3170, 3140, 3060 (NH); 1720 (C=O)	7.40–7.54 (2 H, m, 4'-H and 5'-H), 7.80–7.92 (2 H, m, 2'-H and 6'-H), 8.40 (1 H, s, 3-H), 8.43 (1 H, s, CH-Ar), 10.50 (1 H, br s, 4-NH), 11.01 (1 H, br s, 7-H), 13.10 (1 H, br s, 1-NH)
11k	3170, 3140, 3070 (NH); 1680 (C=O)	7.48 (2 H, d, J 8.6, Ar-mH), 7.87 (2 H, d, J 8.6, Ar-oH), 8.37 (1 H, s, 3-H), 8.45 (1 H, s, CH-Ar), 10.50 (1 H, br, 4-NH), 11.00 (1 H, br, 7-NH), 13.14 (1 H, br, 1-NH)
111	3170, 3140, 3060 (NH); 1685 (C=O)	7.66 (2 H, d, J 8.6, Ar- <i>m</i> H), 7.80 (2 H, d, J 8.6, Ar- <i>o</i> H), 8.38 (1H, s, 3-H), 9.44 (1 H, s, C <i>H</i> -Ar), 10.50 (1 H, br, 4-NH), 11.00 (1 H, br s, 7-NH), 13.11 (1 H, br, 1-NH)
11m	3170, 3140, 3060 (NH); 1685 (C=O)	2.36 (3 H, s, CH ₃), 7.28 (2 H, d, <i>J</i> 7.8, Ar- <i>m</i> H), 7.72 (2 H, d, <i>J</i> 7.8, Ar- <i>o</i> H), 8.35 (1 H, s, 3-H), 8.44 (1 H, s, C <i>H</i> -Ar), 10.45 (1 H, br, 4-NH), 11.00 (1 H, br, 7-NH), 13.10 (1 H, br, 1-NH)
11n ^{<i>a</i>}	3180, 3140, 3080 (NH); 1680 (C=O)	3.80 (3 H, s, OCH ₃), 6.74 (2 H, d, <i>J</i> 8.5, Ar- <i>m</i> H), 7.58 (2 H, d, <i>J</i> 8.5, Ar- <i>o</i> H), 7.94 (1 H, s, 3-H), 7.99 (1 H, s, C <i>H</i> -Ar), 10.06 (1 H, br s, 4-NH), 10.92 (1 H, br s, 7-NH), 12.90 (1 H, br s, 1-NH)
110	3180, 3140, 3070 (NH); 1655 (C=O)	6.09 (2 H, s, OCH ₂ O), 7.00 (1 H, d, <i>J</i> _{5',6'} 8.2, 5'-H), 7.27 (1 H, d, <i>J</i> _{5',6'} 8.2, <i>J</i> _{2',6'} 1.6, 6'-H), 7.45 (1 H, d, <i>J</i> _{2',6'} 1.6, 2'-H), 8.30 (1 H, s, 3-H), 8.45 (1 H, s, CH-Ar), 10.35 (1 H, br, 4-NH), 11.03 (1 H, br s, 7-NH), 13.04 (1 H, br, 1-NH)
11p ^{<i>a</i>}	3165, 3120, 3050 (NH); 1650, 1630 (C=O)	8.00 (4 H, br, Ar-H), 8.50 (2 H, s, 3-H and CH-Ar), 11.25 (1 H, br, 4-NH), 11.95 (1 H, br, 7-NH), 12.35 (1 H, br, COOH), 13.55 (1 H, br, 1-NH)
11q	3160, 3140, 3050 (NH); 1640 (C=O)	6.84 (2 H, d, J 8.4, Ar-mH), 7.65 (2 H, d, J 8.4, Ar-oH), 8.26 (1 H, s, 3-H), 8.41 (1 H, s, CH-Ar), 9.67 (1 H, br s, OH), 10.86 (1 H, br s, 4-NH), 11.02 (1 H, br s, 7-NH), 12.90 (1 H, br, 1-NH)
11r	3165, 3120, 3080 (NH); 1690 (C=O)	8.10 (1 H, d, J 8.8, Ar-oH), 8.30 (1 H, d, J 8.8, Ar-mH), 8.50 (1 H, s, 3-H), 8.52 (1 H, s, CH-Ar), 10.65 (1 H, br, 4-NH), 11.11 (1 H, br, 7-NH), 13.21 (1 H, br, 1-NH)
^a This compour	nd was measured at 60 MHz.	

0.70; v_{max}/cm^{-1} 3410 and 3360 (NH₂), 3200, 3100 and 3040 (NH), 1675 (C=O) and δ_{max}/cm^{-1} 1675 (NH₂); δ_{H} [200 MHz; (CD₃)₂SO] 6.25 (2 H, br, NH₂), 7.94 (1 H, s, 3-H), 8.66 and 10.00 (each 1 H, each br s, 2 × NH) and 13.67 (1 H, br s, 1-NH); m/z (FAB, glycerol matrix) 228 (MH⁺) and 230 (MH⁺ + 2).

3-Amino-7*H*-pyrazolo[4,3-*e*]-1,2,4-triazolo[4,3-*c*]pyrimidin-5(6*H*)-one 10

(1) The reaction mixture in the same reaction and under the same conditions as in the above preparation for **9** was heated under reflux for 36 hours. After the same work-up as noted above, recrystallization of the crude crystals from water gave the *pyrazolotriazolopyrimidine* **10** (0.15 g, 29%) as colourless powdery crystals, mp > 300 °C (Found: C, 37.1; H, 3.1; N, 49.9. C₆H₅N₇O·1/4 H₂O requires C, 36.8; H, 2.8; N, 50.1%); *R*_f (A) 0.57; ν_{max} /cm⁻¹ 3370 and 3260 (NH₂), 3180 and 3100 (NH), 1720 (C=O) and δ_{max} /cm⁻¹ 1685 (NH₂); δ_{H} [200 MHz; (CD₃)₂SO] 7.83 (1 H, s, 9-H), 7.94 (2 H, br s, NH₂), 12.27 (1 H, br s, 6-NH) and 13.10 (1 H, br s, 7-NH); *m/z* (FAB, glycerol matrix) 192 (MH⁺).

(2) A mixture of the pyrazolopyrimidine **9** (0.2 g, 0.88 mmol) and urea (0.16 g, 2.66 mmol) in 2-ethoxyethanol (10 cm³) was heated under reflux for 10 hours. After the same work-up as noted above, recrystallization of the crude crystals from water gave the *pyrazolotriazolopyrimidine* **10** (30 mg, 18%).

4-Alkylidenehydrazino- and 4-arylmethylidenehydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidin-6(7*H*)-ones 11b, e–r. General procedure

A mixture of the hydrazinopyrazolopyrimidine 6 (1.0 g, 6.02

mmol) and an appropriate alkyl aldehyde or aryl aldehyde (9.03 mmol) in DMF (50 cm³) was stirred at room temperature or 40 °C for 10 hours. After the reaction was complete, the solution was evaporated under reduced pressure and the residue was triturated with EtOH or AcOEt to give crystals, which were collected by filtration and recrystallized from an appropriate solvent to afford the corresponding *hydrazones* **11b**, **e**-**r** as shown in Tables 3 and 4.

7*H*-Pyrazolo[4,3-*e*]-1,2,4-triazolo[4,3-*c*]pyrimidin-5(6*H*)-one 12a and its 3-substituted derivatives 12b–s. General procedure

(1) Method A: A mixture of an appropriate 4-alkylidenehydrazino- or 4-arylmethylidenehydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidin-6(7*H*)-one **11b**, **e**-**r** (2.0 mmol) with 70% nitric acid (0.22 cm³, 2.4 mmol) in DMF (30–50 cm³) was heated at 100 °C for 1–9 hours. After the reaction was complete, the precipitated crystals were collected by filtration and combined with further material obtained by concentration of the filtrate under reduced pressure. The crystals were recrystallized from an appropriate solvent to afford the corresponding *pyrazolotriazolopyrimidines* **12b**, **e**-**p**, **r**, **s** as shown in Tables 5 and 6.

(2) Method B: A mixture of an appropriate 4-alkylidenehydrazino- or 4-arylmethylidenehydrazino-1*H*-pyrazolo[3,4-*d*]pyrimidin-6(7*H*)-one **11e**, **g**, **h**, **k**, **m**–**o**, **q** (2.0 mmol) with DEAD (0.35 g, 2.0 mmol) in DMF (50 cm³) was heated under reflux. After heating for several hours, further DEAD (2.0 mmol amounts; total 3–7 equiv.) was added to the heated solution at hourly intervals until the hydrazone **11** disappeared. After the reaction was complete, the solution was evaporated under reduced pressure to leave a solid, which was purified by

Table 5	Preparative,	physical ai	nd analytical	l data for the	e compounds 12a–s
---------	--------------	-------------	---------------	----------------	-------------------

Compound	Reaction conditions ^a			Yield ^a	Decouver en la set b	Found (%) (Required)			m/z	
Compound (Formula)	Method	Temp/°C	Time/h	(%)	Mp/°C	Recrystn. solvent ^b $(R_{\rm f}, {\rm solvent \ system}^{c})$	С	Н	N	MH^+
12 a C ₆ H₄N ₆ O·1/4 H₂O	(C) (D)	r.t. 100	1 1	66 65	>300	DMF (0.32, A)	39.9 (39.9)	2.7 (2.5)	46.5 (46.5)	177
12b C ₇ H ₆ N ₆ O∙1/5 H ₂ O	(A) (C) (D)	100 r.t 100	2.5 1 1	64 83 55	>300	EtOH–DMF (0.38, A)	43.5 (43.4)	3.5 (3.3)	43.7 (43.4)	191
12c C ₈ H ₈ N ₆ O	(<i>D</i>)	100	1	54	>300	EtOH–DMF (0.45, A)	46.8 (47.1)	4.2 (3.95)	41.4 (41.2)	205
12d C ₁₀ H ₁₂ N ₆ O·1/5 H ₂ O	(<i>D</i>)	100	1	55	>300	EtOH–DMF (0.55, A)	51.1 (50.9)	5.5 (5.3)	36.0 (35.6)	233
12e C ₁₃ H ₁₈ N ₆ O·1/4 H ₂ O	(A) (B) (E)	100 reflux 100	3 7 1	77 60 75	>300	EtOH–DMF (0.64, A)	55.7 (56.0)	6.7 (6.7)	30.2 (30.1)	275
12f C ₁₆ H ₂₂ N ₆ O·1/4 H ₂ O	(A)	100	2.5	67	>300	EtOH–DMF (0.34, B)	60.3 (60.3)	7.35 (7.1)	26.3 (26.35)	315
12g C ₁₂ H ₈ N ₆ O/1/4 H ₂ O	(A) (B) (E)	100 reflux 100	1 5 1	91 60 85	>300	water–DMF (0.60, A)	55.9 (56.1)	3.45 (3.3)	32.75 (32.7)	253
12h C ₁₂ H ₇ FN ₆ O∙1/4 H ₂ O	(A) (B) (E)	100 reflux 100	1 8 3	91 65 72	>300	EtOH–DMF (0.62, A)	52.6 (52.5)	2.9 (2.75)	30.65 (30.6)	271
12i C ₁₂ H ₇ ClN ₆ O	(A)	100	2	70	>300	water–DMF (0.63, A)	50.0 (50.3)	2.8 (2.5)	28.9 (29.3)	287/28
12j C₁₂H ₇ ClN ₆ O·1/5 H₂O	(A)	100	2	76	>300	water–DMF (0.64, A)	49.9 (49.65)	2.8 (2.6)	29.2 (28.95)	287/28
12k C ₁₂ H ₇ ClN ₆ O∙1/5 H ₂ O	(A) (B) (E)	100 reflux 100	2 8 1	90 67 71	>300	water–DMF (0.63, A)	49.7 (49.65)	2.8 (2.6)	29.2 (28.95)	287/28
12l C ₁₂ H ₇ BrN ₆ O·1/5 H ₂ O	(A)	100	5	74	>300	EtOH–DMF (0.64, A)	43.2 (43.1)	2.5 (2.2)	24.9 (25.1)	331/33
12m C ₁₃ H ₁₀ N ₆ O∙1/5 H ₂ O	(A) (B) (E)	100 reflux 100	9 9 3	60 54 67	>300	water–DMF (0.67, A)	58.0 (57.9)	4.0 (3.9)	31.3 (31.1)	267
12n C ₁₃ H ₁₀ N ₆ O ₂ ·1/4 H ₂ O	(A) (B) (E)	100 reflux 100	3 9 3	88 57 61	>300	water–DMF (0.60, A)	54.5 (54.45)	3.9 (3.7)	29.3 (29.3)	283
120 C ₁₃ H ₈ N ₆ O ₃ ⋅1/4 H ₂ O	$(A) \\ (B)$	100 reflux	1 9	81 55	>300	EtOH–DMF (0.62, A)	52.2 (51.9)	3.1 (2.85)	28.0 (27.9)	297
12p C ₁₃ H ₈ N ₆ O ₃ ⋅1/3 H ₂ O	(A)	100	1.5	69	>300	EtOH–DMF (0.64, C)	51.8 (51.7)	3.2 (2.9)	27.6 (27.8)	297
12q C ₁₂ H ₈ N ₆ O₂·1/4 H₂O	(<i>B</i>)	reflux	9	50	>300	EtOH–DMF (0.51, A)	52.8 (52.85)	2.9 (3.1)	31.0 (30.8)	269
12r C ₁₂ H ₇ N ₇ O ₃ ·1/4 H ₂ O	$(A) \\ (E)$	100 100	5 5	60 60	>300	EtOH–DMF (0.60, A)	48.1 (47.8)	2.8 (2.5)	32.2 (32.5)	298
12s C ₁₂ H ₇ N ₇ O ₄ •1/4 H ₂ O	(A)	100	1	52	>300	DMF (0.46, A)	45.4 (45.4)	2.6 (2.4)	30.6 (30.9)	314

^{*a*} The reaction conditions and yields depend on the particular method. ^{*b*} All compounds **12** were obtained as colourless powdery crystals except for **12b**, **h**, **k**, **l**, (colourless needles) and **12r**, **s** (yellow powder). ^{*c*} Solvent systems: (A) AcOEt–EtOH (4:1 v/v), (B) AcOEt–EtOH (9:1 v/v), (C) AcOEt– *n*-hexane–AcOH (8:4:1 v/v).

column chromatography on silica gel using AcOEt as eluent and recrystallized from an appropriate solvent to give the corresponding *pyrazolotriazolopyrimidines* **12e**, **g**, **h**, **k**, **m–o**, **q** as shown in Tables 5 and 6. ine **6** (0.60 g, 3.6 mmol) with an appropriate triethyl orthoester (18.0 mmol) in trifluoroacetic acid (9 cm³) was stirred at room temperature for 1 hour. After the reaction was complete, the precipitated crystals were collected by filtration and recrystallized from an appropriate solvent to afford the corre-

(3) Method C: A mixture of the hydrazinopyrazolopyrimid-

Table 6 IR and ¹H NMR spectroscopic data for the compounds 12a-s

Compound	$v_{\rm max}({\rm Nujol})/{\rm cm}^{-1}$	$\delta_{\rm H}$ [200 MHz; (CD ₃) ₂ SO; Me ₄ Si]
12a	3120, 3030 (NH); 1740 (C=O)	8.34 (1 H, s, 9-H), 8.62 (1 H, s, 3-H), 12.58 (1 H, br s, 6-NH), 13.60 (1 H, br s, 7-NH)
12b	3110, 3050 (NH); 1700 (C=O)	2.40 (3 H, s, CH ₃), 8.54 (1 H, s, 9-H), 12.46 (1 H, br s, 6-NH), 13.57 (1 H, br s, 7-NH)
12c	3100, 3060 (NH); 1700 (C=O)	1.29 (3 H, t, J 7.6, CH ₂ CH ₃), 2.77 (2 H, q, J 7.6, CH ₂ CH ₃), 8.57 (1 H, s, 9-H), 12.43 (1 H, br s, 6-NH 13.55 (1 H, br s, 7-NH)
12d	3090, 3060 (NH) 1700 (C=O)	0.92 (3 H, t, <i>J</i> 7.6, CH ₂ CH ₂ CH ₂ CH ₃), 1.36 (2 H, sextet, <i>J</i> 7.6, CH ₂ CH ₂ CH ₂ CH ₃), 1.72 (2 H, quintet, <i>J</i> 7.6, CH ₂ CH ₂ CH ₂ CH ₃), 2.74 (2 H, t, <i>J</i> 7.6, CH ₂ CH ₂ CH ₂ CH ₃), 8.57 (1 H, s, 9-H), 12.44 (1 H, br s, 6-NH 13.55 (1 H, br s, 7-NH)
12e ^{<i>a</i>}	3110, 3070 (NH); 1700 (C=O)	0.86 (3 H, t, <i>J</i> 6.5, CH ₂ CH ₃ [CH ₂] ₄ CH ₃), 1.30 (8 H, br s, CH ₂ CH ₂ [CH ₂] ₄ CH ₃), 1.50–1.80 (2 H, n CH ₂ CH ₂ [CH ₂] ₄ CH ₃), 2.50–2.95 (2 H, m, CH ₂ CH ₂ [CH ₂] ₄ CH ₃), 8.53 (1 H, s, 9-H), 12.41 (1 H, br s, 6-NH 13.50 (1 H, br, 7-NH)
12f	3150, 3070 (NH); 1710 (C=O)	1.28 (10 H, br s, CH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 1.62–1.80 (2 H, m, CH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 1.92 2.06 (2 H, m, CH ₂ CH ₁ [CH ₂] ₅ CH ₂ CH=CH ₂), 2.72 (2 H, t, <i>J</i> 7.3, CH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 4.87–5.0 (2 H, m, CH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 5.66–5.89 (1 H, m, CH ₂ CH ₂ [CH ₂] ₅ CH ₂ CH=CH ₂), 8.57 (1 H, 9-H), 12.43 (1 H, br s, 6-NH), 13.55 (1 H, br s, 7-NH)
12g ^{<i>a</i>}	3150, 3050 (NH); 1720 (C=O)	7.40–7.70 (3 H, m, Ph- <i>m</i> , <i>p</i> H), 7.90–8.35 (2 H, m, Ph- <i>o</i> H), 8.68 (1 H, s, 9-H), 12.60 (1 H, br s, 6-NH 13.60 (1 H, br, 7-NH)
12h ^{<i>a</i>}	3110, 3090 (NH); 1710 (C=O)	7.37 (2 H, dd, J _{H,H} 8.8, J _{H,F} 9.1, Ar- <i>m</i> H), 8.22 (2 H, dd, J _{H,H} 8.8, J _{H,F} 5.9, Ar- <i>o</i> H), 8.66 (1 H, s, 9-H), 12.5 (1 H, br s, 6-NH), 13.65 (1 H, br, 7-NH)
12i	3150, 3070 (NH); 1710 (C=O)	7.44–7.78 (3 H, m, 3'-H, 4'-H and 5'-H), 7.95–8.09 (1 H, m, 6'-H), 8.69 (1 H, s, 9-H), 12.67 (1 H, br 6-NH), 13.58 (1 H, br, 7-NH)
12j ^{<i>a</i>}	3150, 3100 (NH); 1720 (C=O)	7.54–7.63 (2 H, m, 4'-H and 5'-H), 7.95–8.25 (2 H, m, 2'-H and 6'-H), 8.67 (1 H, s, 9-H), 12.62 (1 H, br 6-NH), 13.60 (1 H, br s, 7-NH)
12k	3160, 3100 (NH); 1700 (C=O)	7.62 (2 H, d, J 8.6, Ar- <i>m</i> H), 8.17 (2 H, d, J 8.6, Ar- <i>o</i> H), 8.70 (1 H, s, 9-H), 12.62 (1 H, br s, 6-NH), 13.6 (1 H br s, 7-NH)
121	3150, 3060 (NH); 1720 (C=O)	7.76 (2 H, d, J 8.6, Ar-mH), 8.10 (2 H, d, J 8.6, Ar-oH), 8.69 (1 H, s, 9-H), 12.62 (1 H, br s, 6-NH), 13.6 (1 H, br s, 7-NH)
12m	3180, 3100 (NH); 1720 (C=O)	2.39 (3 H, s, CH ₃), 7.35 (2 H, d, <i>J</i> 8.0, Ar- <i>m</i> H), 8.05 (2 H, d, <i>J</i> 8.0, Ar- <i>o</i> H), 8.66 (1 H, s, 9-H), 12.5 (1 H, br s, 6-NH), 13.61 (1 H, br s, 7-NH)
12n ^{<i>a</i>}	3160, 3100 (NH); 1730 (C=O)	3.85 (3 H, s, OCH ₃), 7.10 (2 H, d, <i>J</i> 8.8, Ar- <i>m</i> H), 8.12 (2 H, d, <i>J</i> 8.8, Ar- <i>o</i> H), 8.64 (1 H, s, 9-H), 12.60 (1 H br s, 6-NH), 13.50 (1 H, br, 7-NH)
120	3160, 3050 (NH); 1720 (C=O)	6.13 (2 H, s, OCH ₂ O), 7.08 (1 H, d, J _{5',6'} 8.1, 5'-H), 7.58 (1 H, d, J _{2',6'} 1.6, 2'-H), 7.72 (1 H, d, J _{5',6'} 8.1, J _{2'} , 1.6, 6'-H), 8.68 (1 H, s, 9-H), 12.55 (1 H, br s, 6-NH), 13.62 (1 H, br s, 7-NH)
12p ^{<i>a</i>}	3160, 3090 (NH); 1700, 1660 (C=O)	8.10 (2 H, d, <i>J</i> 8.8, Ar- <i>m</i> H), 8.32 (2 H, d, <i>J</i> 8.8, Ar- <i>o</i> H), 8.69 (1 H, s, 9-H), 12.70 (1 H, br s, 6-NH), 13.5 (2 H, br, 7-NH and COOH)
12q	3160, 3050 (NH); 1718 (C=O)	6.90 (2 H, d, <i>J</i> 8.8, Ar- <i>m</i> H), 7.99 (2 H, d, <i>J</i> 8.8, Ar- <i>o</i> H), 8.66 (1 H, s, 9-H), 9.94 (1 H, s, OH), 12.51 (1 F br s, 6-NH), 13.60 (1 H, br, 7-NH)
12r ^{<i>a</i>}	3170, 3100 (NH); 1720 (C=O)	8.39 (4 H, br s, Ar-H), 8.69 (1 H, s, 9-H), 12.70 (1 H, br s, 6-NH), 13.60 (1 H, br 7-NH)
12s	3160, 3080 (NH); 1720 (C=O)	7.31 (1 H, d, $J_{5',6'}$ 8.8, 5'-H), 8.28 (1 H, dd, $J_{5',6'}$ 8.8. $J_{2',6'}$ 2.2, 6'-H), 8.60 (1 H, d, $J_{2',6'}$ 2.2, 2'-H), 8.70 (1 H s, 9-H), 11.59 (1 H, s, OH), 12.62 (1 H, br s, 6-NH), 13.65 (1 H, br s, 7-NH)

^a This compound was measured at 60 MHz.

sponding *pyrazolotriazolopyrimidines* **12a**, **b** as shown in Tables 5 and 6.

(4) Method D: A mixture of the hydrazinopyrazolopyrimidine **6** (0.60 g, 3.6 mmol) with an appropriate triethyl or trimethyl orthoester (10.8 mmol) in DMF (30–40 cm³) was heated at 100 °C for 1 hour. After the reaction was complete, the solution was evaporated under reduced pressure and the residue was triturated with EtOH or AcOEt to give crystals, which were collected by filtration and recrystallized from an appropriate solvent to afford the corresponding *pyrazolotriazolopyrimidines* **12a–d** as shown in Tables 5 and 6.

(5) Method E: A mixture of an appropriate 4-alkylidenehydrazino- or 4-arylmethylidenehydrazino-6-chloro-1*H*-pyrazolo[3,4-*d*]pyrimidine 3a-g (2.0 mmol) with 70% nitric acid (0.9 cm³, 10.0 mmol) in DMF (30–50 cm³) was heated at 100 °C for 1–5 hours. After the reaction was complete, the precipitated crystals were collected by filtration and further crystals were obtained by concentration of the filtrate under reduced pressure. The combined crystals were recrystallized from an appropriate solvent to afford the corresponding *pyrazolotriazolopyrimidines* 12e, g, h, k, m, n, r as shown in Tables 5 and 6.

Xanthine oxidase assay

All test compounds and allopurinol were dissolved in dimethyl sulfoxide (DMSO) and diluted with 50 mM sodium phosphate

buffer (pH 7.4) for *in vitro* experiments. The final concentration of DMSO in the reaction solution was 0.1%.

Bovine milk xanthine oxidase (XO) (10 mU ml⁻¹) was incubated with 100 μ M xanthine in the presence and absence of the test compound (0.003–10 μ M) at 25 °C for 15 min. Uric acid formation was determined by absorbance at 292 nm using a Hitachi 228-A spectrophotometer, and the inhibition rate (%) for the formation of uric acid and IC₅₀ values of the test compounds were determined. The inhibition rate (*I*) of the test compound at each concentration was calculated by eqn. (1),

$$I(\%) = 100 - [(D - D_{\rm B})/T] \times 100$$
(1)

where T is the optical density of a solution of xanthine and XO, D is the optical density of a solution of test compound, xanthine and XO and $D_{\rm B}$ is the optical density of a solution of test compound and XO.

The inhibitory activity of allopurinol against bovine milk xanthine oxidase was also examined as a positive control. Each experiment was repeated at least twice at different concentrations (0.003–10 μ M). The values of IC₅₀, *i.e.* the μ M concentration of inhibitor necessary for 50% inhibition, were determined from the dose–response curve from the relation of the logarithmic concentration (μ M) and the inhibition (%).

Table 7	Inhibitory activities of	the compounds 2, 3	, 4 , 6 , 8 , 11 and	d 12 against bo	ovine milk xanthine	oxidase in compa	arison with allopuri	inol

No. 10 3 1 0.3 0.1 0.03 IC g/t 2 21.4 11.8 8.3 >10 >10 >10 >10 3b 7.6 >10 >10 >10 >10 >10 >10 3c 12.0 9.5 9.4 >10 >10 >10 21 16 22.1 >10 21 16 22.1 >10 21 16 22.1 >10 21 16 22.1 >10 21 >10 21 16 22.1 >10 21 >10 21 16 22.1 >10 21 16 22.4 16 22.4 10 >10 21 16 22.4 16 21 >10 21 16 21 >10 21 16 21 10 21 16 25.8 13.3 0.43 13 0.44 21 21 21 21 21 21 21 21 <	Compound No.	Inhibition (%)						
		10	3	1	0.3	0.1	0.03	IC ₅₀ /µм
	2	21.4	11.8	8.3				>10
$3c$ 21.0 16.0 11.5 >10 $3d$ 12.0 9.5 9.4 >10 $3c$ 14.2 13.8 10.8 >10 4^a 39.8 22.1 >10 6 24.1 >10>10 $8b$ 7.2 >10 $8b$ 7.2 >10 $8d$ 12.4 >10 $8f$ 17.2 >10 $8f$ 17.2 >10 $11b$ 58.6 45.0 34.8 15.8 6.9 6.2 4.67 $11g$ 75.6 73.0 66.3 49.8 29.9 0.33 $11g$ 75.6 73.0 66.3 49.8 29.9 0.33 $11g$ 67.6 66.4 63.4 53.8 36.3 0.07 $11j$ 67.6 66.5 61.8 52.8 70.7 0.22 $11k$ 66.1 65.6 62.9 53.8 39.5 22.7 0.22 $11h$ 68.9 66.5 63.8 52.8 70.0 18.6 0.24 $11n$ 74.5 73.3 70.0 59.2 41.0 0.17 $11n$ 68.1 65.2 60.3 48.2 40.3 16.7 0.33 $11p$ 68.1 65.2 60.3 48.2 40.3 16.7 0.33 $11p$ 68.1 65.9 61.6 47.0 29.0 14.1 0.38 $11n$ 74.5 73.3 70.0 59.2 41.0 0.17	3b	7.6						>10
3d12.09.59.4>103e14.213.810.8>103f41.0>104"39.822.1624.1>108b7.2>108c16.3>108f17.2>108f17.2>1011b58.645.034.815.86.96.224.413.09.74.67.8511e71.769.260.644.625.813.30.4311f53.336.522.413.09.74.67.8511g75.673.066.349.829.90.330.1411i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k66.165.663.852.837.018.60.2411m74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811p68.165.260.346.829.314.80.3311g68.165.250.344.232.90.1211b68.465.961.647.029.014.10.3811p68.165.250.346.829.314.8		21.0	16.0	11.5				>10
3e 14.2 13.8 10.8 > 0 3f 41.0 > 0 4" 39.8 > 0 6 24.1 > 0 8b 7.2 > 0 8c 16.3 > 0 8d 12.4 > 0 8f 17.2 > 0 11b 58.6 45.0 34.8 15.8 6.9 6.2 4.6 7.8 11g 53.3 36.5 22.4 13.0 9.7 4.6 7.8 11g 75.6 73.0 66.3 49.8 29.9 0.33 11i 68.5 69.9 63.6 47.0 29.7 0.37 11j 67.6 66.4 63.4 54.2 38.3 36.0 0.0 11j 67.6 66.4 63.4 52.8 37.0 0.33 11i 68.9 66.5 63.8 52.8 37.0 0.22 11m 74.5 73.3 70.0 59.2 41.0 0.17 11a 65.2		12.0	9.5	9.4				>10
3f41.0>10 4^a 39.822.1624.1>108b7.2>108c16.3>108d12.4>108f17.2>1011b58.645.034.815.86.96.24.611e71.769.260.644.625.813.30.4311g75.673.066.349.829.90.3011h68.569.963.647.029.70.3711i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k66.165.663.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811q62.866.260.348.240.316.70.3311q62.866.260.348.224.316.70.3311q68.165.260.348.224.316.70.3311q68.165.260.348.229.014.10.3811q68.465.265.152.537.320.70.2212a69.267.555.252.022.2	3e	14.2	13.8	10.8				
4^{a} 39.8 22.1 6 24.1 >10 $8b$ 7.2 >10 $8c$ 16.3 >10 $8d$ 12.4 >10 $8f$ 17.2 >10 $11b$ 58.6 45.0 34.8 15.8 6.9 6.2 4.67 $11g$ 75.6 73.0 66.3 49.8 29.9 0.30 $11i$ 68.5 69.9 63.6 47.0 29.7 0.37 $11i$ 68.9 69.6 68.5 64.4 53.8 36.3 0.00 $11i$ 66.1 65.6 62.9 53.8 39.5 22.7 0.22 $11k$ 66.1 65.6 62.9 53.8 39.5 22.7 0.22 $11m$ 74.5 73.3 70.0 59.2 41.0 0.17 $11m$ 68.4 65.9 61.6 47.0 29.0 14.1 0.38 $11p$ 68.1 65.2 60.3 48.2 40.3 16.7 0.33 <	3f	41.0						>10
8b7.2>108c16.3>108f17.2>1011b58.645.034.815.86.96.24.611e71.769.260.644.625.813.30.4311f53.336.522.413.09.74.67.8811g75.673.066.349.829.90.3311i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.260.348.240.316.70.3311p68.165.260.348.240.316.70.3311q62.866.260.348.240.316.70.3311g66.865.152.537.320.70.2212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2312c ^{er} 57.055.252.042.228.817.80.7812d'71.568.867.764.656.739.60.0012f66.865.0<								
8b7.2>108c16.3>108f17.2>1011b58.645.034.815.86.96.24.611e71.769.260.644.625.813.30.4311f53.336.522.413.09.74.67.8811g75.673.066.349.829.90.3311i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.260.348.240.316.70.3311p68.165.260.348.240.316.70.3311q62.866.260.348.240.316.70.3311g66.865.152.537.320.70.2212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2312c ^{er} 57.055.252.042.228.817.80.7812d'71.568.867.764.656.739.60.0012f66.865.0<	6	24.1						>10
8c16.3>108d12.4>108f17.2>1011b58.645.034.815.86.96.24.6711e71.769.260.644.625.813.30.4511f53.336.522.413.09.74.67.8811g75.673.066.349.829.90.3311h68.569.963.647.029.70.3711i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.663.852.837.018.60.2411m74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811q62.866.260.346.829.314.80.3311q62.866.260.346.829.314.80.3311q68.165.260.346.829.314.80.3311q68.465.939.528.714.01.9212a69.267.565.256.641.823.90.1612a69.267.565.256.641.823.90.1612a69.267.565.256.641.823.90.1612a69.869.167.9 <td></td> <td>7.2</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		7.2						
8d12.4>108f17.2>1011b58.645.034.815.86.96.24.6711e71.769.260.644.625.813.30.4311f53.336.522.413.09.74.67.8511g75.673.066.349.829.90.3311h68.569.963.647.029.70.3711i67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k66.165.663.852.837.018.60.2411m74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811p68.165.260.348.240.316.70.3311q62.866.260.348.240.316.70.3311q63.865.152.537.320.70.2212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212a69.869.167.962.854.440.20		16.3						
8f17.2>1011b58.645.034.815.86.96.24.6711e71.769.260.644.625.813.30.4411f53.336.522.413.09.74.67.8811g75.673.066.349.829.90.3311i68.569.963.647.029.70.3311i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k66.165.662.953.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3311p68.165.260.346.829.314.80.3311q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212c57.055.252.042.228.817.80.7512d57.655.153.064.134.918.90.5512c <td< td=""><td></td><td>12.4</td><td></td><td></td><td></td><td></td><td></td><td>>10</td></td<>		12.4						>10
11b58.645.034.815.86.96.24.6711e71.769.260.644.625.813.30.4311f53.336.522.413.09.74.67.8811g75.673.066.349.829.90.3011h68.569.963.647.029.70.3711i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211k66.165.663.852.837.018.60.2411m74.573.370.059.241.00.1711o68.465.260.346.829.314.80.3911p68.165.260.348.240.316.70.3311q62.866.260.348.240.316.70.3312a69.267.565.256.641.823.90.1812a69.267.565.256.641.823.90.1812a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212a69.267.565.256.641.823.90.1812b71.568.865.152.5<	8f	17.2						>10
Ite71.769.260.644.625.813.30.43Iff53.336.522.413.09.74.67.89Ig75.673.066.349.829.90.331h68.569.963.647.029.70.371i68.969.668.564.453.836.30.071j67.666.463.454.238.720.70.221k66.165.662.953.839.522.70.221m68.966.563.852.837.018.60.241m74.573.370.059.241.00.171o68.465.961.647.029.014.10.381q62.866.260.348.240.316.70.331g67.352.146.939.528.714.01.921a69.267.565.256.641.823.90.181zb71.568.865.152.537.320.70.2212c69.869.167.962.854.440.20.0612t66.565.063.459.648.432.00.111g67.665.152.537.320.70.2212a69.267.565.256.641.823.90.1612t68.865.152.537.320.70.			45.0	34.8	15.8	6.9	6.2	4.670
11f53.336.522.413.09.74.67.8811g75.673.066.349.829.90.3011h68.569.963.647.029.70.3711i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211m68.966.563.852.837.018.60.2411m74.573.370.059.241.00.1711o68.465.260.346.829.314.80.3311q68.165.260.346.829.314.80.3311q68.165.260.348.240.316.70.3511r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512c c 57.055.252.042.228.817.80.7512d d 57.655.153.046.134.918.90.5512c c 57.668.86		71.7		60.6		25.8	13.3	0.450
11g75.673.066.349.829.90.3311h68.569.963.647.029.70.3711i68.569.963.647.029.70.3711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211h45.144.242.149.640.123.9>1011m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.260.346.829.314.80.3311q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212c ^c 57.055.252.042.228.817.80.7812d ^d 57.655.153.046.134.918.90.5212c69.869.167.764.656.739.60.0012t66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012t68.865.063.459.6 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>4.6</td> <td>7.894</td>							4.6	7.894
11n68.569.963.647.029.70.3711i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211i45.144.242.149.640.123.9>1011m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3311q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212c57.055.252.042.228.817.80.7812d ^d 57.655.153.046.134.918.90.5212c69.869.167.962.854.440.20.0612t68.568.667.163.554.838.90.0712t69.568.667.163.554.838.90.0712t68.969.668.866.761.347.40.0012t68.568.6 <t< td=""><td></td><td></td><td></td><td></td><td></td><td>29.9</td><td></td><td>0.305</td></t<>						29.9		0.305
11i68.969.668.564.453.836.30.0711j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211m45.144.242.149.640.123.9>1011m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3311q68.165.260.346.829.314.80.3911q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212c57.055.252.042.228.817.80.7812d66.865.063.459.648.432.00.1112g67.865.364.259.854.440.20.0012f66.865.063.459.648.432.00.1112g67.865.364.259.854.440.20.0012t68.568.667.764.656.739.60.0012i68.568		68.5	69.9		47.0	29.7		0.373
11j67.666.463.454.238.720.70.2211k66.165.662.953.839.522.70.2211l*45.144.242.149.640.123.9>1011m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3511q62.866.260.346.829.314.80.3911r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212c ^c 57.055.252.042.228.817.80.7812d ^d 57.655.153.046.134.918.90.5212c69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^c 72.370.670.368.362.949.30.0312i68.5		68.9				53.8	36.3	0.077
11k66.165.662.953.839.522.70.22111b45.144.242.149.640.123.9>1011m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811q62.866.260.346.829.314.80.3511q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512c ^c 57.655.153.046.134.918.90.5212d ^d 57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0012f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012i68.568.667.163.554.838.90.0012i68.568.667.163.554.838.90.0012i68.568.667.163.554.838.90.0012i68.5 <td>11i</td> <td>67.6</td> <td></td> <td>63.4</td> <td>54.2</td> <td>38.7</td> <td>20.7</td> <td>0.223</td>	11i	67.6		63.4	54.2	38.7	20.7	0.223
11145.144.242.149.640.123.9>1011m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711068.465.961.647.029.014.10.3811p68.165.260.346.829.314.80.3911q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2212c ^c 57.055.252.042.228.817.80.7812d ^d 57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.868.667.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312i68.969.668.666.661.046.30.0412a71.6 </td <td>11k</td> <td>66.1</td> <td></td> <td>62.9</td> <td>53.8</td> <td>39.5</td> <td>20.7</td> <td>0.223</td>	11k	66.1		62.9	53.8	39.5	20.7	0.223
11m68.966.563.852.837.018.60.2411n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811p68.165.260.346.829.314.80.3311q62.866.260.348.240.316.70.3511r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512c c 57.055.252.042.228.817.80.7512d d 57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0012f66.865.364.259.849.732.40.1112g67.865.364.259.849.732.40.1012i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k c 72.270.770.067.060.946.00.0412i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k c <td>111^b</td> <td>45.1</td> <td></td> <td>42.1</td> <td>49.6</td> <td>40.1</td> <td>23.9</td> <td></td>	111 ^b	45.1		42.1	49.6	40.1	23.9	
11n74.573.370.059.241.00.1711o68.465.961.647.029.014.10.3811p68.165.260.346.829.314.80.3911q62.866.260.348.240.316.70.3311r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512c'57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012i68.568.867.764.656.739.60.0012i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312i'70.166.467.463.960.448.90.0312i'70.270.770.067.060.946.00.0412i'69.668.666.661.046.30.0312i'69.668.666.661.046.30.0312i'70.270.770.0 <td></td> <td>68.9</td> <td></td> <td>63.8</td> <td>52.8</td> <td>37.0</td> <td></td> <td>0.247</td>		68.9		63.8	52.8	37.0		0.247
110 68.4 65.9 61.6 47.0 29.0 14.1 0.38 11p 68.1 65.2 60.3 46.8 29.3 14.8 0.35 11q 62.8 66.2 60.3 48.2 40.3 16.7 0.35 11r 57.3 52.1 46.9 39.5 28.7 14.0 1.92 12a 69.2 67.5 65.2 56.6 41.8 23.9 0.18 12b 71.5 68.8 65.1 52.5 37.3 20.7 0.25 $12c^c$ 57.0 55.2 52.0 42.2 28.8 17.8 0.78 $12d^d$ 57.6 55.1 53.0 46.1 34.9 18.9 0.52 $12c^c$ 69.8 69.1 67.9 62.8 54.4 40.2 0.06 $12f$ 66.8 65.0 63.4 59.6 48.4 32.0 0.11 $12g$ 67.8 65.3 64.2 59.8 49.7 32.4 0.10 $12h$ 69.5 68.8 67.7 64.6 56.7 39.6 0.03 $12i$ 68.5 68.6 67.1 63.5 54.8 38.9 0.07 $12i$ 68.5 68.6 67.4 63.9 60.4 48.9 0.03 $12h$ 69.5 68.6 67.4 63.9 60.4 48.9 0.03 $12i$ 68.5 68.6 66.6 66.6 61.0 46.0 0.04					59.2		10.0	0.172
11p 68.1 65.2 60.3 46.8 29.3 14.8 0.39 11q 62.8 66.2 60.3 48.2 40.3 16.7 0.35 11r 57.3 52.1 46.9 39.5 28.7 14.0 1.92 12a 69.2 67.5 65.2 56.6 41.8 23.9 0.18 12b 71.5 68.8 65.1 52.5 37.3 20.7 0.25 12c ^c 57.0 55.2 52.0 42.2 28.8 17.8 0.78 12d ^d 57.6 55.1 53.0 46.1 34.9 18.9 0.52 12e 69.8 69.1 67.9 62.8 54.4 40.2 0.06 12f 66.8 65.3 64.2 59.6 48.4 32.0 0.11 12g 67.8 65.3 64.2 59.8 49.7 32.4 0.10 12h 69.5 68.8 67.7 64.6 56.7 39.6 0.006 12i 68.5 68.6 67.1 63.5 54.8 38.9 0.07 12j 68.9 69.6 68.8 66.7 61.3 47.4 0.03 $12kr$ 72.2 70.7 70.0 67.0 60.9 46.0 0.04 $12ms$ 72.2 70.7 70.0 67.0 60.9 46.0 0.04 $12p$ 69.6 68.6 68.6 66.6 61.0 46.3 0.04 <t< td=""><td></td><td></td><td></td><td></td><td>47.0</td><td></td><td>14 1</td><td>0.385</td></t<>					47.0		14 1	0.385
$11q$ 62.866.260.348.240.316.70.35 $11r$ 57.352.146.939.528.714.01.92 $12a$ 69.267.565.256.641.823.90.18 $12b$ 71.568.865.152.537.320.70.25 $12c^c$ 57.055.252.042.228.817.80.76 $12d^d$ 57.655.153.046.134.918.90.52 $12e$ 69.869.167.962.854.440.20.00 $12f$ 66.865.063.459.648.432.00.11 $12g$ 67.865.364.259.849.732.40.10 $12h$ 69.568.867.764.656.739.60.06 $12i$ 68.568.667.163.554.838.90.07 $12j$ 68.969.668.866.761.347.40.03 $12k^e$ 72.370.670.368.362.949.30.03 $12k^g$ 72.270.770.067.060.946.00.04 $12n$ 71.671.070.466.958.642.30.05 $12k^e$ 72.270.770.067.060.946.00.04 $12k^e$ 72.270.770.067.060.946.00.04 $12k^e$ 72.270.770.067.060.9 <t< td=""><td></td><td>68.1</td><td></td><td></td><td>46.8</td><td>29.3</td><td>14.8</td><td>0.399</td></t<>		68.1			46.8	29.3	14.8	0.399
11r57.352.146.939.528.714.01.9212a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512c ^c 57.055.252.042.228.817.80.7812d ^d 57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0612f66.865.364.259.648.432.00.1112g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0312i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.270.770.067.060.946.00.0412m71.671.070.466.958.642.30.0512u69.067.165.769.060.650.234.30.0512u69.668.666.661.046.30.0412u71.671.070.466.958.642.30.0512u69.067.165.769.060.450.234.30.0512u69.668.666.661.046.30.040.3		62.8		60.3	48.2	40.3	16.7	0.359
12a69.267.565.256.641.823.90.1812b71.568.865.152.537.320.70.2512c57.055.252.042.228.817.80.7812d69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312lf66.467.463.960.448.90.0312j68.969.668.866.761.347.40.0312k ^e 72.270.770.067.060.946.00.0412m71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0512a69.668.666.661.046.30.0412a71.671.070.466.958.642.30.0512a69.067.1 <td></td> <td>57.3</td> <td>52.1</td> <td>46.9</td> <td>39.5</td> <td>28.7</td> <td>14.0</td> <td>1.925</td>		57.3	52.1	46.9	39.5	28.7	14.0	1.925
12b71.568.865.152.537.320.70.2512c57.055.252.042.228.817.80.7812d57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312lf70.166.467.463.960.448.90.0312m71.671.070.466.958.642.30.0512a69.067.165.760.650.234.30.0512a69.067.165.760.650.234.30.0512a69.067.165.760.650.234.30.0512a69.668.666.661.046.30.0412b69.067.165.760.650.234.30.0512b69.067.165.760.650.234.30.0512b69.0<		69.2			56.6	41.8	23.9	0.184
$12c^e$ 57.055.252.0 42.2 28.8 17.8 0.78 $12d^d$ 57.655.153.0 46.1 34.9 18.9 0.52 $12e$ 69.8 69.1 67.9 62.8 54.4 40.2 0.06 $12f$ 66.8 65.0 63.4 59.6 48.4 32.0 0.11 $12g$ 67.8 65.3 64.2 59.8 49.7 32.4 0.10 $12h$ 69.5 68.8 67.7 64.6 56.7 39.6 0.06 $12i$ 68.5 68.6 67.1 63.5 54.8 38.9 0.07 $12j$ 68.9 69.6 68.8 66.7 61.3 47.4 0.03 $12k^e$ 72.3 70.6 70.3 68.3 62.9 49.3 0.03 $12k^r$ 72.2 70.7 70.0 67.0 60.9 46.0 0.04 $12n$ 71.6 71.0 70.4 66.9 58.6 42.3 0.05 $12o$ 70.2 69.6 68.6 66.6 61.0 46.3 0.04 $12p$ 69.0 67.1 65.7 60.6 50.2 34.3 0.05 $12a^{h}$ 69.6 68.6 66.6 61.0 46.3 0.04 $12p$ 69.0 67.1 65.7 60.6 50.2 34.3 0.05 $12a^{h}$ 69.6 68.6 66.6 61.0 42.9 0.05 $12a^{h$		71.5			52.5	37.3	20.7	0.250
12d ^d 57.655.153.046.134.918.90.5212e69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312k ^f 70.166.467.463.960.448.90.0312m ^g 72.270.770.067.060.946.00.0412n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0512a69.668.666.661.042.90.0512a69.868.268.764.457.539.60.0512a69.868.268.764.457.539.60.0612a69.169.769.067.764.046.90.03				52.0	42.2		17.8	0.782
12e69.869.167.962.854.440.20.0612f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312l ^f 70.166.467.463.960.448.90.0312m ^g 72.270.770.067.060.946.00.0412n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0512a69.668.268.764.457.539.60.0512a69.868.268.764.457.539.60.0512s69.169.769.067.764.046.90.03	12d ^d					34.9		0.529
12f66.865.063.459.648.432.00.1112g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312k ^f 70.166.467.463.960.448.90.0312m ^g 72.270.770.067.060.946.00.0412n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0912q ^h 67.666.065.462.957.042.90.0512x69.868.268.764.457.539.60.0012s69.169.769.067.764.046.90.03		69.8						0.069
12g67.865.364.259.849.732.40.1012h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312l ^f 70.166.467.463.960.448.90.0312m ^g 72.270.770.067.060.946.00.0412n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0512q ^h 67.666.065.462.957.042.90.0512r69.868.268.764.457.539.60.0612s69.169.769.067.764.046.90.03		66.8	65.0	63.4	59.6	48.4	32.0	0.117
12h69.568.867.764.656.739.60.0612i68.568.667.163.554.838.90.0712j68.969.668.866.761.347.40.0312k ^e 72.370.670.368.362.949.30.0312h ^f 70.166.467.463.960.448.90.0312m ^g 72.270.770.067.060.946.00.0412n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0512q ^h 67.666.065.462.957.042.90.0512r69.868.268.764.457.539.60.0612s69.169.769.067.764.046.90.03		67.8		64.2	59.8	49 7	32.4	0.103
12i 68.5 68.6 67.1 63.5 54.8 38.9 0.07 12j 68.9 69.6 68.8 66.7 61.3 47.4 0.03 $12k^e$ 72.3 70.6 70.3 68.3 62.9 49.3 0.03 $12l^f$ 70.1 66.4 67.4 63.9 60.4 48.9 0.03 $12m^g$ 72.2 70.7 70.0 67.0 60.9 46.0 0.04 $12n$ 71.6 71.0 70.4 66.9 58.6 42.3 0.05 $12o$ 70.2 69.6 68.6 66.6 61.0 46.3 0.04 $12p$ 69.0 67.1 65.7 60.6 50.2 34.3 0.09 $12q^h$ 67.6 66.0 65.4 62.9 57.0 42.9 0.05 $12r$ 69.8 68.2 68.7 64.4 57.5 39.6 0.06 $12s$ 69.1 69.7 69.0 67.7 64.0 46.9 0.03	12h	69.5			64.6	56.7	39.6	0.062
12j68.969.668.866.761.347.40.0312k*72.370.670.368.362.949.30.0312lf70.166.467.463.960.448.90.0312m*72.270.770.067.060.946.00.0412n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0912qh67.666.065.462.957.042.90.0512r69.868.268.764.457.539.60.0612s69.169.769.067.764.046.90.03		68.5					38.9	0.002
$12k^e$ 72.370.670.368.362.949.30.03 $12l^f$ 70.166.467.463.960.448.90.03 $12m^g$ 72.270.770.067.060.946.00.04 $12n$ 71.671.070.466.958.642.30.05 $12o$ 70.269.668.666.661.046.30.04 $12p$ 69.067.165.760.650.234.30.09 $12q^h$ 67.666.065.462.957.042.90.05 $12r$ 69.868.268.764.457.539.60.06 $12s$ 69.169.769.067.764.046.90.03		68.9			66 7		47.4	0.038
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$12_{\rm J}$ $12k^{e}$	72.3			68.3			0.032
$12m^g$ 72.270.770.067.060.946.00.04 $12n$ 71.671.070.466.958.642.30.05 $12o$ 70.269.668.666.661.046.30.04 $12p$ 69.067.165.760.650.234.30.09 $12q^h$ 67.666.065.462.957.042.90.05 $12r$ 69.868.268.764.457.539.60.06 $12s$ 69.169.769.067.764.046.90.03	12k 12l ^f						48.9	0.032
12n71.671.070.466.958.642.30.0512o70.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0912q ^h 67.666.065.462.957.042.90.0512r69.868.268.764.457.539.60.0612s69.169.769.067.764.046.90.03		72.2			67.0		46.0	
12070.269.668.666.661.046.30.0412p69.067.165.760.650.234.30.0912q ^h 67.666.065.462.957.042.90.0512r69.868.268.764.457.539.60.0012s69.169.769.067.764.046.90.03				70.0	66.9	58.6		
12p 69.0 67.1 65.7 60.6 50.2 34.3 0.09 12q ^h 67.6 66.0 65.4 62.9 57.0 42.9 0.05 12r 69.8 68.2 68.7 64.4 57.5 39.6 0.06 12s 69.1 69.7 69.0 67.7 64.0 46.9 0.03		70.2			66.6			
$12q^h$ 67.666.065.462.957.042.90.05 $12r$ 69.868.268.764.457.539.60.06 $12s$ 69.169.769.067.764.046.90.03		69.0						
12r 69.8 68.2 68.7 64.4 57.5 39.6 0.06 12s 69.1 69.7 69.0 67.7 64.0 46.9 0.03	12p	67.6					34.3 12 0	
12s 69.1 69.7 69.0 67.7 64.0 46.9 0.03	12y 12r	60.9	68.2	68 7	64.4	57.0	42.9 30.6	
		60 1	60.2		67 7	57.5		
$A \parallel_{O}^{I}$ 28.2 10.0 0.0 4.6 2.2 24.2	Allo ⁱ	38.2	69.7 19.9	9.9	4.6	3.2	40.9	24.3

^{*a*} 30 μм: 53.9%, 100 μм: 63.9%. ^{*b*} This value is inaccurate because of insolubility in DMSO. ^{*c*} 0.01 μм: 12.6%. ^{*d*} 0.01 μм: 9.6%. ^{*e*} 0.01 μм: 30.4%, 0.003 μм, 16.4%. ^{*f*} 0.01 μм: 37.3%. ^{*g*} 0.01 μм: 28.2%, 0.003 μм: 13.6%. ^{*b*} 0.01 μм: 29.0%. ^{*i*} Allo: allopurinol.

Acknowledgements

We are grateful to the SC-NMR Laboratory of Okayama University for 200 MHz proton NMR experiments. This work was supported in part by a Grant-in-Aid for Scientific Research (C) (No. 09680570) from the Japan Society for the Promotion of Science.

References

- 1 Part 2, T. Nagamatsu, H. Yamasaki, T. Fujita, K. Endo and H. Machida, J. Chem. Soc., Perkin Trans. 1, 1999, 3117.
- 2 R. W. Rundles, J. B. Wyngaarden, G. H. Hitchings, G. B. Elion and H. R. Silberman, *Trans. Assoc. Am. Physicians*, 1963, **76**, 126.
- 3 T. F. Yü and A. B. Gutman, Am. J. Med., 1964, 37, 885.
- 4 J. R. Klinenberg, S. E. Goldfinger and J. E. Seegmiller, Ann. Intern. Med., 1965, 62, 639.
- 5 G. B. Elion, Ann. Rheumat. Dis., 1966, 25, 608.
- 6 G. B. Elion, S. Callahan, H. Nathan, S. Bieber, R. W. Rundles and G. H. Hitchings, *Biochem. Pharmacol.*, 1963, 12, 85.
- 7 J. L. Young, R. B. Boswell and A. S. Nies, Arch. Intern Med., 1974, 134, 553.

- 8 K. R. Hande, R. M. Noone and W. J. Stone, Am. J. Med., 1984, 76, 47
- 9 D. E. Duggan, R. M. Noll, J. E. Baer, F. C. Novello and J. J. Baldwin, J. Med. Chem., 1975, 18, 900.
- 10 R. L. Wortmann, A. S. Ridolfo, R. W. Lightfoot Jr. and I. H. Fox, J. Rheumatol., 1985, 12, 540.
- 11 A. Bindoli, M. Valente and L. Cavallini, *Pharmacol. Res. Commun.*, 1985, 17, 831.
- 12 T. Spector, W. W. Hall, D. J. Porter, C. U. Lambe, D. J. Nelson and T. A. Krenitsky, *Biochem. Pharmacol.*, 1989, **38**, 4315.
- 13 S. Sato, K. Tatsumi and T. Takahashi, *Purine and Pyrimidine Metabolism in Man VII, Part A: Chemotherapy, ATP Depletion and Gout*, eds. R. A. Harkness, G. B. Elion and N. Zöllner, Plenum Press, New York, 1991, p. 135.
- 14 Y. Osada, M. Tsuchimoto, H. Fukushima, K. Takahashi, S. Kondo, M. Hasegawa and K. Komoriya, *Eur. J. Pharmacol.*, 1993, 241, 183.
- 15 G. Biagi, I. Giorgi, O. Livi, V. Scartoni, I. Tonetti and L. Costantino, *Farmaco*, 1995, 50, 257.
- 16 T. Nagamatsu, Y. Watanabe, K. Endo and M. Imaizumi, PCT Int. Appl. WO 96 26,208/1996 (Chem. Abstr., 1996, 125, 247848j).
- 17 T. Nagamatsu, T. Abiru, Y. Watanabe and K. Endo, Jpn. Kokai Tokkyo Koho JP 07,242,694/1995 (Chem. Abstr., 1996, 124, 117896s).

- 18 T. Nagamatsu and T. Fujita, Chem. Commun., 1999, 1461.
- 19 G. A. Bhat and L. B. Townsend, J. Chem. Soc., Perkin Trans. 1, 1981, 2387.
- 20 F. Gatta, M. Luciani and G. Palazzo, J. Heterocycl. Chem., 1989, 26, 613.
- 21 U. D. Treuner and H. Breuer, USP 4 053 474, 1977 (Chem. Abstr., 1977, 88, 37826s), USP 4 124 764, 1978 (Chem. Abstr., 1978, 90,

87508b) Ger. Offen. 2838029, 1979 (Chem. Abstr., 1979, 91, 39492r).

- 22 F. Yoneda, Y. Sakuma, S. Mizumoto and R. Ito, *J. Chem. Soc.*, *Perkin Trans. 1*, 1976, 1805.
 23 R. K. Robins, *J. Am. Chem. Soc.*, 1956, **78**,784.

Paper a907673e